SID99511

ID: ALA789

Chembl Id: CHEMBL789

Cas Number: 3130-96-9

PubChem CID: 861

Max Phase: Phase

Molecular Formula: C15H12I3NO4

Molecular Weight: 650.98

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Dl-triiodothyronine | Liothyronine, dl- | Rathyronine|3130-96-9|dl-triiodothyronine|Liothyronine, dl-|2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid|NSC46046|O48UO55HR0|Detrothyronin|Rathyroninum|Ratironina|Thrithyrone|DL-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine|Triiodo-L-thyronine|(+)-Triiodothyronine|Rathyronine [INN:DCF]|Rathyroninum [INN-Latin]|Ratironina [INN-Spanish]|Dextro-3:5:3'-triiodothyronine|UNII-O48UO55HR0|NSC80203|NSC-46046|3,3',5-TriiodothyroShow More⌵

Canonical SMILES:  NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O

Standard InChI:  InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)

Standard InChI Key:  AUYYCJSJGJYCDS-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA789

   RATHYRONINE

2. Alternative Forms:

   

   ALA789

   Sodium 2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 650.98

Molecular Weight (Monoisotopic): 650.7901

AlogP: 3.95

#Rotatable Bonds: 5

Polar Surface Area: 92.78

Molecular Species: ZWITTERION

HBA: 4

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 0.30

CX Basic pKa: 9.48

CX LogP: 2.80

CX LogD: 2.76

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.43

Np Likeness Score: 0.63

References

1. PubChem BioAssay data set, 

2. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

3. Kubinyi H, Kehrhahn OH..  (1976)  Quantitative structure-activity relationships. 1. The modified Free-Wilson approach.,  19  (5): [PMID:1271399] [10.1021/jm00227a003]

4. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

5. Sampathi Perera KLI, Hanson AM, Lindeman S, Imhoff A, Lu X, Sem DS, Donaldson WA..  (2018)  Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-β agonists (SERBAs).,  157  [PMID:30144697] [10.1016/j.ejmech.2018.08.006]

6. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of NIH (USA) - Clinical Collection,  [10.6019/CHEMBL4513141]

7. Wang Y, Qin L, Chen W, Chen Q, Sun J, Wang G..  (2021)  Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1.,  226  [PMID:34517305] [10.1016/j.ejmech.2021.113806]

Source

Source(5):

• Scientific Literature
• PubChem BioAssays
• USP Dictionary of USAN and International Drug Names
• AstraZeneca Deposited Data
• CO-ADD antimicrobial screening data